Skin / Drugs

Bonti Announces Results of Phase 2a Scar Reduction Clinical Study

Posted On: Aug 10, 2018   |   Posted By: Surgical Aesthetics Magazine

Bonti Announces Results of Phase 2a Scar Reduction Clinical Study

Bonti, a privately held, clinical-stage biotechnology company, announced topline results of its SHINE-1 (Scar Healing Improvement with Neurotoxin E) Phase 2a clinical trial, which evaluated the company's EB-001A for scar reduction following Mohs surgery. EB-001, the active ingredient in EB-001A, is a novel botulinum neurotoxin serotype E with a unique clinical profile, characterized by a faster onset of action and a shorter duration of activity compared to botulinum neurotoxin serotype A products.
For the randomized, placebo-controlled, double-blind trial, EB-001A or placebo was administered to the frontalis muscle immediately after Mohs surgery for skin lesions in the forehead in 12 subjects. Subjects were followed up to 90 days post-treatment. Per the company's release, EB-001A was well tolerated with no drug-related adverse events. It appeared to provide maximum benefit during the acute scar formation phase as the...

Continue reading ...